Aduro Biotech , Inc. Protocol ADU-CL-02-v8 CRS-207 with Pemetrexed and Cisplatin CLINICAL PROTOCOL TITLE OF STUDY: A Phase 1B Study to Evaluate the Safety and Induction of Immune Response of CRS-207 in Combination with Pemetrexed and Cisplatin as Front-line Therapy in Adults with Malignant Pleural Mesothelioma Protocol ID: Sponsor: IND: Date of Issue: Affiliation Sponsor: ADU-CL-02 Aduro Biotech, Inc. 740 Heinz Avenue Berkeley, CA 94710-2224 Phone: 510-848-4400 13,389 08 March 2018, Version 8 Signatures of Approval for Protocol (Version 8) Name Signature Natalie Sacks, MD l'v~ ,j~~ Date: C)g Mr)_.(_ "1ol? NCT Number: NCT01675765 Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page ii This study is to be performed in accordance with Good Clinical Practice, the ethical principles that have their origin in the Declaration of Helsinki: Title 21 of the Code of Federal Regulations (CFR) Parts 50 (Protection of Human Subjects), 56 ( IRBs), and 312 ( INDA ); and ICH E6 (Guideline for Good Clinical Practice). Study Sponsor: Aduro Biotech , Inc.